Suggested remit - To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for untreated non-squamous non-small-cell lung cancer
Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1495
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 January 2020 | Suspended. Topic has been suspended |
| 22 January 2020 | Note added to the project documents |
| 18 July 2019 - 15 August 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 June 2019 | Note added to the project documents |
| 11 January 2019 | Note added to the project documents |
| 02 October 2018 - 30 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 October 2018 | Note added to the project documents |
| 24 April 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual